AI-Bio
The single most exciting private name in AI-bio — Chai-2/3 is the first AI antibody platform with a wet-lab-validated, repeatedly-improving hit rate AND signed pharma revenue (Lilly + Pfizer); the bet is whether a portable, lab-light software platform can defend value capture against Isomorphic's deeper engine and the platform-vs-asset value trap. WATCHING for an IPO that is 2-3 years away.
Research
The verdict
The single most exciting private name in AI-bio — Chai-2/3 is the first AI antibody platform with a wet-lab-validated, repeatedly-improving hit rate AND signed pharma revenue (Lilly + Pfizer); the bet is whether a portable, lab-light software platform can defend value capture against Isomorphic's deeper engine and the platform-vs-asset value trap. WATCHING for an IPO that is 2-3 years away.
Chai Discovery is an AI-native molecular-design company — building foundation models that turn drug discovery from wet-lab trial-and-error into a software-design problem. Founded March 2024, HQ San Francisco, ~31 employees as of Apr 2026. The framing the founders use: a "computer-aided design suite for molecules" — the AutoCAD-for-biology analogy.
What they actually sell — two products, two motions:
Business model — two-pronged:
Customers / partners (the proof points):
Why this is interesting (the MenFem teaching frame): the conventional view is "AI drug discovery has overpromised for a decade — Recursion, Exscientia, BenevolentAI all underdelivered." The contrarian read is that those were target-ID and small-molecule screening plays; Chai is doing something narrower and more falsifiable — designing a protein binder that you can synthesize in a 24-well plate and measure binding on within two weeks. The feedback loop is short, the result is physical, and the hit rate is going up release-over-release. That is a different category of claim.
For an AI-bio platform the "supply chain" is compute → data → model → wet-lab validation → pharma deployment. Named stakeholders along the chain:
n/a — specific cloud/GPU vendor not disclosed.Single-source dependency: the PDB/SAbDab commons (everyone shares it) and — critically — pharma partners as the sole source of the developability data that turns a binder into a drug. That dependency is the supply-chain risk and the moat question in one.
Be honest: in a field where everyone trains on the same public structures and models leapfrog every ~6 months, the data moat is weak by construction. So where could a durable edge actually live?
Bargaining power: today Chai needs pharma more than pharma needs Chai — Lilly/Pfizer have alternatives (Isomorphic, internal teams, AlphaFold3) and own the proprietary data. The leverage only flips if Chai-designed molecules start reaching the clinic and working, which is a decade away. Net: the moat is "stay ahead + lock in proprietary data via partners." Both are contestable. This is a great team renting an edge, working to convert it into an owned one.
n/a — private; no segment-level financial disclosure. No segments.csv data (header only). Qualitatively, two revenue lines exist:
Geographic split: US-centric (SF), with a UK research footprint via OpenBind. n/a — not disclosed.
The "earnings" of a private is its round history. Chai's trajectory is steep and tier-1-validated:
| Round | Amount | Post-money valuation | Lead(s) | Date |
|---|---|---|---|---|
| Seed | ~$30M | ~$150M | Thrive Capital, OpenAI, Dimension | 2024 |
| Series A | $70M | ~$550M | Menlo Ventures (Anthology Fund) | Aug 2025 |
| Series B | $130M | $1.3B | Oak HC/FT + General Catalyst | Dec 2025 |
| Total | ~$231M | — | — | as of Apr 2026 |
Runway: not disclosed; estimate multi-year given a fresh $130M B and a thin team.For Chai the "pipeline" is the model line and its wet-lab-validated capability, not clinical assets (it has none in the clinic). The capability table:
| Model | Released | Headline result | Provenance |
|---|---|---|---|
| Chai-1 | Sep 2024 | PoseBusters protein-ligand 77% (≈AF3's 76%); CASP15 monomer lDDT 0.849; antibody-antigen DockQ>0.8 on 17% of 152 held-out complexes (~2x AF2) | |
| Chai-2 | Jun 2025 | ~16% zero-shot de novo antibody hit rate (15.5% avg; 20% VHH / 13.7% scFv) across 52 novel targets with no known PDB binders; binders for 50% of targets in a 2-week cycle; 68% on miniproteins; ~100x over prior compute methods | |
| Chai-2 (Nov 2025) | Nov 2025 | Full-length IgGs at maintained hit rates; functional GPCR agonists for 2 receptors w/o HTS; pMHC selectivity; >85% of hits met developability criteria | |
| Chai-3 | Jun 2026 | Doubles Chai-2's success rate; therapeutic-standard antibodies; multi-specifics; hard-to-drug targets; better generalization |
The de-risking question (the one that matters): is the hit rate improving and generalizing? Evidence says yes — 17% → 34% structural accuracy, ~0.1% → 16% → (Chai-3) ~30%+ design hit rate, and developability now >85%. That trajectory, not any single number, is the bull thesis.
No earnings calls. The sentiment proxy is founder communication + scientific publishing cadence:
Comps are by category, not P/E (nobody here has earnings). USD valuations are secondary/round marks, ``:
| Company | Founded | Valuation (latest) | Edge / posture | Note |
|---|---|---|---|---|
| Chai Discovery | 2024 | $1.3B (Dec 2025 B) | Zero-shot antibody design, open Chai-1, lab-light, Lilly+Pfizer | Subject |
| Isomorphic Labs | 2021 | ~$3B secondary (Apr 2026); $600M Series A Mar 2025 (Thrive) | DeepMind spinout (Hassabis); IsoDDE (Feb 2026) claims 3x Chai-1, 2.3x AF3, 19.8x Boltz-2 on protein-ligand high-fidelity; Lilly+Novartis+J&J deals | The dangerous one |
| Xaira Therapeutics | 2023/24 | ~$2.7B secondary (Apr 2026); $1B launch | David Baker (Nobel '24); RFdiffusion/RFantibody; training code exclusive to Xaira; builds wet lab | Asset + platform |
| EvolutionaryScale | 2023 | $142M seed (Jun 2024) | ESM3; team acquired by Chan Zuckerberg Initiative Nov 2025 | Effectively absorbed |
| Generate:Biomedicines | 2018 | IPO'd Feb 2026 (~$400M raised) | Platform→asset pivot; now public | Public comp |
| Nabla Bio | 2020 | $26M Series A (2024); ~$37M total | JAM/JAM-2; 39% VHH-Fc hit rate on 923+ designs; AstraZeneca/BMS/Takeda (2nd Takeda Oct 2025: dbl-digit M upfront + >$1B milestones) | Direct antibody rival; strong hit data |
| Absci | 2011 (public) | Mkt cap ~$560M (Apr 2026) | Origin-1 (on Boltz-1); zero-prior-epitope; owns wet lab | Public, asset-light→assets |
| Boltz / (MIT-origin) | 2024 | $28M seed (Jan 2026) | Open-source Boltz-1/2; Boltz-2 nears FEP accuracy; Pfizer partner | Open-source threat to Chai-1 |
| Big Hat Biosciences | 2019 | ~$99M total | ML + high-speed wet lab; Lilly antibody deal Apr 2025 | Lab-in-loop rival |
Reading the table: Chai is mid-pack on valuation ($1.3B) but arguably top-tier on the specific axis it competes on (wet-lab-validated zero-shot antibody hit rate with signed pharma revenue). Isomorphic is bigger, better-capitalized, and claims a 3x structural-prediction edge over Chai-1 — but Isomorphic's public proof is mostly structure/affinity prediction, whereas Chai's is generative design validated in a plate. Different proof, overlapping ambition. Nabla's 39% VHH hit rate is a genuine flag that Chai's lead is contestable.
Crossover-fund marks: GC + Oak HC/FT (B) and Menlo (A) are the IPO-proximity tells. No public mutual-fund markup yet. Secondary marks: n/a — not disclosed.
Mapping the "stock-moving" events for a private (each step-changed perceived value):
Pattern: the market re-rates Chai on (1) a published wet-lab hit-rate step-change and (2) a named pharma signing. Those are the two catalyst types to watch. The next re-rate is either Chai-3 wet-lab numbers in print, a third major pharma, or the first Chai-designed molecule entering IND-enabling studies.
Joshua Meier — CEO/co-founder. The signal hire of the field. Google Science Fair finalist at 16; founded a biotech (Provita) in high school; Harvard + Feng Zhang's CRISPR lab; OpenAI (2018, research/eng); co-led ESM1 at Meta (first transformer protein LM); Chief AI Officer at Absci where he worked on de novo antibody design tied to clinical molecules. Founder-archetype, technical, with a prior in exactly this problem — not a generalist parachuting into bio. Skin in the game: founder equity, undisclosed %.
Jack Dent — President/co-founder. Harvard CS classmate of Meier; cold-emailed into Stripe as a teenager, built Stripe Link + Stripe Capital + large-scale ML infra. The systems/commercial half — explains the unusually clean enterprise motion (Lilly/Pfizer signed fast for a 2-yr-old).
Matt McPartlon — CTO. De novo antibody design at Absci; protein-protein interaction models at VantAI/Proxima. Jacques Boutreau — generative molecular affinity (McGill/Aqemia).
Board: Mikael Dolsten, Pfizer's former Chief Scientific Officer, joined at Series A — and Pfizer is now a customer. That is either the best possible validation or a related-party flag worth noting (an ex-Pfizer-CSO board member while Pfizer becomes a paying licensee). I read it as validation, but flag it.
Capital allocation: disciplined — 31 people on $231M, lab-light, spending on compute + talent not real estate or a wet lab. No buybacks/M&A (too early). Red flags: none material; the only watch-items are (a) the Dolsten/Pfizer adjacency and (b) the founders' youth + first-time-CEO status against a giant TAM and brutal competition. Archetype: mission-driven technical founders with a genuine domain prior and a commercial co-founder. For this stage, close to ideal.
Accounting: n/a — private, unaudited, no financial statements. No revenue-recognition, lease, SBC, or goodwill analysis is possible without filings; none invented.
Regulatory findings (from regulatory/regulatory-findings.md, generated 2026-06-24):
"Chai Discovery" (FTC OR DOJ OR FDA OR CFPB OR consent decree OR settlement OR fine OR penalty) enforcement: no material enforcement, litigation, fine, or consent-decree hits surfaced across this and the Phase A–B searches.The real "forensic" risks for a company like this are scientific, not accounting — and the skeptic literature flags them precisely (carried into Lens 13):
Verdict on the books: clean on the (nonexistent) accounting; the diligence burden is entirely on whether the science generalizes beyond favorable targets and survives the developability funnel. "No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and (n/a — no 10-K) as of 2026-06-24."
Where it is: post-Series B, ~$1.3B, two flagship pharma deals (Lilly + Pfizer) producing real ARR, a model cadence that's still accelerating. Stage: late-private, commercially-validated, pre-IPO.
IPO-readiness: MEDIUM, and rising — but an S-1 is ~2–3 years out. What gates it:
Estimated tradeable window: 2028–2029. Be-early action: this is exactly the name to track now — there is no public way to own it, and the watch is when (pre-IPO secondary, or the eventual IPO), not if it's interesting.
Write-back note:
research/private-watch.jsondoes not exist / has no chai-discovery entry. Per wave boundaries I do not edit watchlist/private-watch state from this run — flag for the curator to addchai-discoverywithstage: late-private,ipo_readiness: medium,catalyst: "ARR scale + first Chai-designed molecule into IND-enabling studies",dossier: companies/chai-discovery/deep-dive-2026-06-24.md.
Forecast (Brier): skipping forecast.ts create (no EPS for a private; per --watchlist/private rules, log forecasts only on a binary). Candidate binary for a future log: "Chai Discovery signs a 3rd top-15-pharma licensing deal by 2026-12-31" — p≈0.55; not logged this run.
Bull case. Chai is the first AI-antibody platform to clear the bar that killed a decade of AI-bio hype: a wet-lab-validated, generalizing, release-over-release-improving design hit rate (~0.1% → 16% → ~30%+), and a real enterprise business (Lilly mid-eight-figures + Pfizer) at <2.5 years old. The team is the best-pedigreed in the field (ESM1 + Stripe + Absci). The TAM is enormous — mAbs were $288B in 2024 → ~$628B by 2035, 23% of 2025 drug approvals were antibodies. If the partnership model converts proprietary developability data into a compounding edge, and if even one Chai-designed molecule reaches the clinic, this re-rates from "$1.3B AI tool" to "the antibody-design layer of the pharma industry." The open Chai-1 funnel + the licensing engine is a clean software business with biotech-scale upside.
Bear case (3 things that permanently impair it):
Pre-mortem (it's Dec 2027 and the thesis broke): Chai-4 lands ~level with Chai-3 (the hit-rate curve flattened — favorable targets were the easy 80%); Isomorphic's IsoDDE-derived design tool overtakes it; Lilly renews at a lower fee because internal teams + AlphaFold closed the gap; the Pfizer deal lapses; and zero Chai molecules reached the clinic, so the platform never earned a royalty. The $1.3B looks like a 2025 AI-bubble mark.
Is the multiple too high? On traction (one sized deal + one undisclosed), $1.3B is rich — it's priced on the trajectory and the team, not the book. Defensible only if you believe the hit-rate curve keeps bending and the licensing line compounds.
Contrarian view (what the market is refusing to see): the bears anchor on "platforms capture no value" — but that precedent is from the small-molecule + target-ID era, where the platform's contribution was fuzzy and hard to attribute. Zero-shot de novo design is different: the binder didn't exist until the model drew it. Attribution is clean, which makes a defensible, higher royalty (and renewable annual licenses) more plausible than the Schrödinger analogy implies. If Chai is the company that proves "AI designed this drug from scratch" with a clinical asset, the value-capture math the bears use breaks in Chai's favor.
Short thesis: Chai is a brilliant research group with a fragile business priced like a winner.
The one scenario that permanently impairs it: the hit-rate curve flattens at the favorable-target ceiling and Isomorphic/Xaira ship a generative design tool at parity — Chai loses its only real moat (being ahead) with no asset ownership to fall back on. Plausibility: moderate. It's the bet that has to be wrong for the bull case to win.
A fortress-margin vertical-SaaS monopoly trading at a growth-stock funeral price (~20x forward EPS, near 52-wk lows) because the market is pricing a Salesforce-Agentforce CRM war that threatens the contested ~40% (Commercial) while ignoring the defensible, faster-growing ~60% (R&D/Quality); BULLISH at $153 on a 1–3Y view, but the CRM-migration-to-2030 is a real, watchable execution overhang — not a phantom.
A real, fast-growing oncology-data + diagnostics franchise wrapped in an "AI" narrative it can't yet monetize — own the genomics flywheel, but the round-trip-flavored deals, 30-vote founder, and a CEO famous for cashing out cap the multiple until cash flow turns.
Not a tools company anymore — a sub-NAV cash shell mid-conversion into Treeline's oncology pipeline; the only edge is the deal-spread between ~$325M market cap and the ~$460M net cash being delivered, and that spread is a bet on Bilenker's KRAS/BCL6 readouts, not on CyTOF.